Targeting Janus kinases in the treatment of autoimmune disease

Key Takeaways for GI Nurses

• Janus kinase (JAK) inhibitors are an increasingly important drug class for treating inflammatory bowel disease (IBD), a condition frequently managed in GI practices and seen in patients presenting for endoscopic evaluation and surveillance.
• Understanding that JAK inhibitors work by blocking cytokine signaling (including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 pathways) helps nurses anticipate the immunomodulatory effects these medications have on patients' infection risk, wound healing, and overall immune status during procedures.
• Patients on JAK inhibitor therapy for IBD or other autoimmune conditions (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) may require modified pre-procedure screening, infection precautions, and careful medication reconciliation before endoscopic interventions.
• Familiarity with this foundational research supports better patient education conversations, as patients increasingly ask about "newer" oral therapies compared to traditional biologics for their IBD management.

Clinical Relevance

This research summary highlights the scientific foundation behind JAK inhibitor therapies that GI nurses encounter with growing frequency in clinical practice. Since IBD—including Crohn's disease and ulcerative colitis—is explicitly named among the autoimmune conditions driven by cytokine dysregulation, this work has direct relevance to the endoscopy unit. Patients with IBD undergo frequent surveillance colonoscopies, and many are now prescribed JAK inhibitors as part of their maintenance therapy. Nurses conducting pre-procedure assessments should understand that these medications suppress immune signaling pathways, which may influence decisions around antibiotic prophylaxis, infection screening (including tuberculosis and viral reactivation risk), and post-procedure monitoring for delayed healing or infection.

From an operational standpoint, awareness of JAK inhibitor mechanisms supports more informed medication reconciliation during intake. Unlike biologics that are typically held or timed around infusion schedules, JAK inhibitors are oral medications with different half-lives and discontinuation considerations before procedures involving sedation or biopsy. GI nurses who understand the pharmacologic class—rather than just recognizing a drug name—are better equipped to communicate effectively with gastroenterologists about timing of doses relative to scheduled procedures, and to counsel patients accurately when they ask why their medication regimen matters for their upcoming colonoscopy or endoscopy.

Professionally, this research also underscores the value of continuing education around immunology and cytokine biology for endoscopy nurses. As the IBD patient population increasingly transitions to targeted small-molecule therapies, understanding the "why" behind these drugs—not just the "what to watch for"—enhances clinical judgment, supports patient safety, and strengthens the nurse's role as an active member of the multidisciplinary IBD care team, particularly in patient education around infection risk, vaccination timing, and symptom reporting.

Bottom Line

JAK inhibitors represent a scientifically validated and expanding treatment option for IBD and other autoimmune diseases, and GI nurses should be prepared to incorporate awareness of these medications into pre-procedure screening, patient education, and care coordination, recognizing that their immunomodulatory mechanism carries implications for infection risk and perioperative management during endoscopic care.